NCT06143735 - A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2026

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Efgbemalenograstim alfa

Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.

Trial Locations (10)

Unknown

Henan Provincial People's Hospital, Zhengzhou

Hubei Cancer Hospital, Wuhan

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot

Shengjing Hospital of China Medical University, Shenyang

the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Shandong Cancer Hospital & Institute, Jinan

Sichuan Cancer Hospital, Chengdu

Sichuan Provincial People's Hospital, Chengdu

Ningbo No.2 Hospital, Ningbo

Tianjin Medical University Cancer Institute and Hospital, Tianjin